|
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
|
23 August 2018 |
|
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
|
30 July 2018 |
|
Novartis renews drug donation of Egaten® (triclabendazole) until 2022
|
23 July 2018 |
|
Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
|
28 June 2018 |
|
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
|
26 June 2018 |
|
Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
|
18 June 2018 |
|
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
|
04 June 2018 |
|
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
|
28 May 2018 |
|
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
|
21 May 2018 |
|
Alcon Cares Project 100 commits to reducing cataract blindness globally
|
10 May 2018 |